Last quarter (Q2 2023), Processa Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Processa Pharmaceuticals's net income was $-2.61M. See Processa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 10.47M	$ 20.26M	$ 12.13M	$ 6.44M	$ 3.94M	$ 4.52M
Operating Income	$ -10.47M	$ -27.53M	$ -12.13M	$ -6.44M	$ -3.94M	$ -4.52M
Net Non Operating Interest Income Expense	$ 92.24K	$ 101.20K	$ 11.63K	$ -277.95K	$ -25.11K	$ -142.91K
Other Income Expense	$ 7.11M	$ 7.30M	$ -163.77K	$ -8.70M	-	-
Pretax Income	$ -25.67M	$ -27.42M	$ -11.96M	$ -15.41M	$ -3.96M	$ -4.67M
Tax Provision	-	$ -7.45M	$ -530.61K	$ -1.00M	$ -602.72K	$ -902.80K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -17.49M	$ -27.46M	$ -11.43M	$ -19.04M	$ -3.86M	$ -3.77M
Basic EPS	$ -1.46	$ -1.70	$ -0.75	$ -2.54	$ -0.70	$ -0.71
Diluted EPS	$ -0.65	$ -1.70	$ 0.00	$ -2.54	$ -0.70	$ -0.71
Basic Average Shares	$ 82.02M	$ 16.11M	$ 15.32M	$ 7.50M	$ 5.53M	$ 5.33M
Diluted Average Shares	$ 65.91M	$ 16.11M	$ 15.32M	$ 7.50M	$ 5.53M	$ 5.33M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.47M	$ 20.26M	$ 12.13M	$ 6.44M	$ 3.94M	$ 4.52M
Net Income From Continuing And Discontinued Operation	$ -25.70M	$ -27.42M	$ -11.43M	$ -14.41M	$ -3.36M	$ -3.77M
Normalized Income	$ -6.02M	-	-	$ -6.28M	$ -3.36M	$ -3.77M
Interest Expense	-	-	-	$ 281.12K	$ 36.66K	$ 161.21K
EBIT	$ -25.76M	$ -27.42M	$ -11.97M	$ -15.13M	$ -3.92M	$ -4.51M
EBITDA	$ -25.33M	$ -26.52M	$ -11.18M	$ -14.33M	$ -3.12M	$ -3.88M

Currency in USD

Processa Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing